Skip to content
AnalystLens

Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2024

Filing Date
Filed August 6, 2024
Period End
June 30, 2024
Security
HALO
One revenue dollarkept$0.40
In the record · 2016–202610-K1110-Q328-K140

HALO filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 140 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported second-quarter 2024 total revenues of $231.4 milliona, up from $221.0 million in the prior-year quarter, and net income of $93.2 million, or $0.72 per diluted share, versus $74.8 million, or $0.56 per diluted share, a year earlier.

Royalties rose to $124.9 millionb from $111.7 million, driven by continued uptake of Phesgo by Roche and the recent launches of VYVGART Hytrulo by argenx and Teriparatide by Teva in the U.S. Proprietary product sales grew to $44.1 million from $32.3 million, while bulk rHuPH20 sales and device partnered product sales declined on timing of partner demand. Revenues under collaborative agreements fell to $27.5 million from $35.4 million, which management attributed to the timing of milestones achieved. For the first six months of 2024, total revenues were $427.2 million and net income was $170.1 million, or $1.32 per diluted share.

Cash, cash equivalents and marketable securities totaled $529.0 millionc at June 30, 2024, and the company stated these balances are sufficient to fund operations for at least the next twelve months. Net cash provided by operating activities was $185.2 million for the six months. The company completed its December 2021 $750.0 million share repurchase program in June 2024 and authorized a new $750.0 million program in February 2024.

Long-term debt, net, was $1.50 billiond, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028. Management noted that the company expects royalty revenue to grow as partner product sales of DARZALEX SC and Phesgo increase and as recently launched partner products, including VYVGART Hytrulo, Tecentriq SC and Ocrevus SC, ramp. The filing also states that a newly issued European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029, and that the company is not party to any legal proceedings expected to have a material adverse effect.

Key Highlights

  1. Total revenues for Q2 2024 were $231.4 million, up from $221.0 million in Q2 2023.
  2. Royalties increased to $124.9 million in Q2 2024 from $111.7 million, a 12% increase, driven by Phesgo and recent launches of VYVGART Hytrulo and Teriparatide.
  3. Net income for Q2 2024 was $93.2 million, or $0.72 per diluted share, compared with $74.8 million, or $0.56 per diluted share, in Q2 2023.
  4. Proprietary product sales rose 37% to $44.1 million in Q2 2024, while bulk rHuPH20 sales fell 9% and device partnered product sales fell 30%.
  5. Revenues under collaborative agreements decreased to $27.5 million from $35.4 million, primarily due to the timing of milestones achieved.
  6. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, with management stating this is sufficient for at least the next twelve months.
  7. The company completed its December 2021 $750.0 million share repurchase program in June 2024 and authorized a new $750.0 million program in February 2024.

Follow one dollar

Of each $1.00 of revenue in Q2 FY2024, Halozyme Therapeutics kept $0.40.

  1. Revenue$231.4M100.0%
  2. Cost of revenue−$39.6M17.1%
  3. Gross profit$191.7M82.9%
  4. Operating costs−$74.5M32.2%
  5. Operating income$117.2M50.7%
  6. Interest, other & tax−$24.0M10.4%
  7. Net income$93.2M40.3%
Computed from 10-QQ2 FY2024filed August 6, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q2 FY2024 against Q2 FY2023

Line itemQ2 FY2024Q2 FY2023Change
Revenue$231.35M$221.04M+4.7%
Cost of Revenue$39.61M$50.07M−20.9%
Gross Profit$191.75M$170.97M+12.2%
R&D Expenses$21.04M$19.73M+6.6%
SG&A Expenses$35.71M$38.95M−8.3%
Operating Expenses$114.12M$126.58M−9.8%
Operating Income$117.23M$94.46M+24.1%
Net Income$93.25M$74.75M+24.7%
EPS (Basic)$0.73$0.57+28.1%
EPS (Diluted)$0.72$0.56+28.6%
Shares Outstanding (Basic)127.12M131.73M−3.5%
Shares Outstanding (Diluted)129.22M133.54M−3.2%

Frequently Asked Questions

  1. What drove the growth in Halozyme's royalty revenue in the second quarter of 2024?

    The filing attributes the 12% increase in royalties, to $124.9 million from $111.7 million, primarily to continued sales uptake of Phesgo by Roche in all geographies and the recent launches of VYVGART Hytrulo by argenx and Teriparatide by Teva in the U.S. Management expects royalty revenue to grow further as sales of DARZALEX SC and Phesgo increase and as recently launched partner products such as Tecentriq SC and Ocrevus SC ramp.

  2. Why did revenues under collaborative agreements decline in the second quarter?

    Revenues under collaborative agreements fell to $27.5 million from $35.4 million, a 22% decrease. The filing states the decline was primarily due to the timing of milestones achieved, and management expects these revenues to continue to fluctuate based on partners' clinical and regulatory milestones.

  3. How much cash and liquidity does Halozyme have, and is it sufficient?

    As of June 30, 2024, cash, cash equivalents and marketable securities totaled $529.0 million. Management believes these resources will be sufficient to fund operations for at least the next twelve months, supplemented by anticipated collaboration revenues and possible future financings.

  4. What is the status of the company's share repurchases?

    The December 2021 $750.0 million repurchase program was completed in June 2024, with a total of 19.1 million shares repurchased at an average price of $39.31 per share. In February 2024, the Board authorized a new program to repurchase up to $750.0 million of common stock.

  5. What is the company's debt position?

    Long-term debt, net, was $1.50 billion at June 30, 2024, consisting of $805.0 million principal of 0.25% Convertible Notes due 2027 and $720.0 million principal of 1.00% Convertible Notes due 2028. The $1.0 million revolving credit facility under the 2022 Facility was undrawn as of June 30, 2024.